Skip to main content

Benitec Plans to Advance Lung Cancer Drug into Clinic

Premium

Benitec Biopharma this week announced that it intends to move its non-small cell lung cancer drug candidate Tribetarna into clinical trials following positive preclinical data generated in collaboration with the Children’s Cancer Institute Australia.

The company said it will use a clinical research organization to manage a planned phase I/IIa study of the expressed RNAi drug, which could begin in the fourth quarter of 2014.

Start of that trial, however, will depend on Benitec obtaining needed funding, it said.

In April, the company announced that Tribetarna, which beta III tubulin, boosted the survival of an orthotopic mouse cancer model when used in combination with chemotherapy, compared with chemotherapy alone (GSN 4/11/2013).

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.